IceCure Medical Announces Publication Of Investigator-Initiated Study Evaluating ProSense For Treatment Of Non-Cancerous Breast Tumors, Or Fibroadenomas

Treatment with ProSense® resulted in 92.9% volume reduction of fibroadenoma one-year post-cryoablation

Findings may impact treatment guidelines issued by medical societies for large non-cancerous breast tumors; study is believed to be the first to evaluate larger lesions and use multiple cryoprobe relocations

ProSense® Cryoablation has FDA-clearance for fibroadenomas

CAESAREA, Israel, March 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the publication of an independent, investigator-initiated study evaluating ProSense® for the treatment of non-cancerous breast tumors,  or fibroadenomas. The study, titled "Cryoablation for fibroadenoma with liquid nitrogen-based system: A retrospective analysis of prospectively collected data," was published in the peer-reviewed journal PLOS One.